Drug intelligence / Profile preview

lofexidine

Development stage
Approved
Lead developer
US WorldMeds
Modality
Small Molecules
Administration
Oral
01

Overview

Lofexidine is a centrally acting alpha2-adrenergic receptor agonist used primarily for the symptomatic treatment of acute opioid withdrawal syndrome in adults. It works by stimulating alpha-2 adrenergic receptors in the brain, which reduces the release of norepinephrine and attenuates the sympathetic stress response associated with opioid withdrawal. This action helps to alleviate symptoms such as stomach cramps, muscle spasms or twitching, yawning, runny eyes, trouble sleeping, and pounding heart that occur when opioids are discontinued abruptly. Lofexidine is a non-opioid medication and does not treat opioid addiction itself but can be used as part of a comprehensive program for opioid use disorder[1][2][3][4][5]. It was originally developed as an antihypertensive agent but was repurposed due to its efficacy in managing withdrawal symptoms with fewer side effects than clonidine[4]. The drug is available by prescription only and is typically administered orally for up to 14 days during detoxification[1][7].

Brand names
Lucemyra
Other names
lofexidinelofexidine hydrochloride
02

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1D (5-hydroxytryptamine receptor 1D)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)ADRA1A (α1A)ADRA2A (α2A)

Beyond the preview

Go deeper on lofexidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lofexidine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call